Thermo Fisher Scientific (TMO) Cash from Financing Activities (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Cash from Financing Activities for 18 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $1.1 billion, up 1171.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.0 billion (up 159.06% YoY), and the FY2025 annual result was $1.8 billion, up 126.52% from the prior year.
• Cash from Financing Activities was $1.1 billion for Q1 2026 at Thermo Fisher Scientific, down from $3.5 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $3.5 billion in Q4 2025 and troughed at -$3.7 billion in Q4 2024.
• Average Cash from Financing Activities over 5 years is -$607.6 million, with a median of -$991.0 million recorded in 2025.
• Year-over-year, Cash from Financing Activities tumbled 2406.58% in 2022 and soared 1328.48% in 2023.
• Over 5 years, Cash from Financing Activities stood at $2.4 billion in 2022, then plunged by 159.72% to -$1.4 billion in 2023, then tumbled by 156.72% to -$3.7 billion in 2024, then soared by 196.18% to $3.5 billion in 2025, then tumbled by 69.0% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $1.1 billion in Q1 2026, $3.5 billion in Q4 2025, and -$632.0 million in Q3 2025.